Everything below concerns GHK-Cu. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-28. Numbers and descriptions here follow the published literature rather than marketing material.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
| Property | Value | Notes |
|---|---|---|
| INCI name | Copper tripeptide-1 | Standard designation on cosmetic ingredient labels |
| Peptide sequence | Gly-His-Lys | Three-residue ligand; binding occurs at the histidine side chain |
| Metal-to-peptide ratio | 1 to 1 | One copper(II) ion per peptide unit |
| Appearance | Blue to violet powder | Colour arises from copper-to-peptide electronic transitions |
| Water solubility | Freely soluble | Commonly formulated in aqueous or water-alcohol systems |
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide was isolated from human plasma in the early 1970s by Loren Pickart, who observed that a plasma fraction from young donors stimulated growth in cultured liver cells. The copper-bound form is abbreviated GHK-Cu, while the metal-free peptide is written simply as GHK. In the research literature the complex also appears as copper tripeptide-1 and as glycyl-histidyl-lysine copper complex.
Copper(II) binds the peptide through four nitrogen donors: the terminal amino group, the imidazole nitrogen of histidine, and two deprotonated amide nitrogens of the peptide backbone. This tetradentate arrangement gives a roughly square-planar geometry, the thermodynamically favoured form near neutral pH. Because the amide nitrogens must lose a proton before they can coordinate, complex formation is strongly pH-dependent, and the fully coordinated species dominates only above mildly acidic conditions. Electronic transitions within the copper d orbital set produce the characteristic blue to violet colour in aqueous solution.
GHK-Cu is a coordination complex formed from the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, the terminal amino group, and the deprotonated amide nitrogen. This arrangement creates a square-planar or distorted geometry around the metal center, depending on pH and the presence of competing ligands. The complex occurs naturally in human plasma, saliva, and urine at low concentrations, and its sequence is conserved across many vertebrate species.
Discovery of GHK is generally attributed to work in the 1970s that isolated a plasma factor influencing liver cell behavior. Subsequent studies identified the copper-binding tripeptide and its ability to chelate copper with high affinity. Early reports linked the complex to wound healing and tissue remodeling in animal models. The free peptide and the copper-bound form have different properties, so the two are distinguished in the literature. Whether endogenous GHK-Cu serves a single primary physiological role remains an open question.
The Valve Index is a discontinued virtual reality headset created and manufactured by Valve. Announced on April 30, 2019, it was released on June 28 of the same year. The Index is a second-generation headset and the first to be fully manufactured by Valve. Half-Life: Alyx is bundled with the headset. In November 2025, Valve announced a successor, the Steam Frame, scheduled for launch in early 2026.
== Biosynthesis == The biosynthesis of thebaine starts with the amino acid tyrosine and proceeds via reticuline in a pathway leading to many benzylisoquinoline alkaloids. The final step is catalysed by the enzyme thebaine synthase, which forms a 2,3-dihydrofuran ring with loss of a molecule of acetic acid from 7-O-acetylsalutaridinol. The reaction occurs spontaneously in alkali but requires catalysis to occur rapidly under physiological conditions near pH 7.
An early attempt in the direction of elastic-plastic fracture mechanics was Irwin's crack extension resistance curve, Crack growth resistance curve or R-curve. This curve acknowledges the fact that the resistance to fracture increases with growing crack size in elastic-plastic materials. The R-curve is a plot of the total energy dissipation rate as a function of the crack size and can be used to examine the processes of slow stable crack growth and unstable fracture. However, the R-curve was not widely used in applications until the early 1970s. The main reasons appear to be that the R-curve depends on the geometry of the specimen and the crack driving force may be difficult to calculate.
Sources: en.wikipedia.org
"... It has been said, and is still being obstinately repeated by anti-Zionists again and again, that Zionism aims at the creation of an independent "Jewish State". But this is wholly fallacious. The "Jewish State" was never part of the Zionist programme. The "Jewish State" was the title of Herzl's first pamphlet, which had the supreme merit of forcing people to think. This pamphlet was followed by the first Zionist Congress, which accepted the Basle programme—the only programme in existence." At the San Remo conference of 19–26 April 1920, the principal Allied and Associated Powers mandated the creation of a Jewish homeland. Britain officially committed itself to the objective set out in the Balfour Declaration by insisting on its forming the basis of the Mandate for Palestine, which was formally approved by the League of Nations in June 1922. The preamble of the Mandate declared:
== Adverse effects == Adverse effects almost solely occur in humans that suffer from glucose-6-phosphate dehydrogenase deficiency. This deficiency causes a shortage of glutathione in erythrocytes and glutathione is needed for the neutralization of ROS (reactive oxygen species) created by the strongly oxidizing agent divicine. Glucose-6-phosphate dehydrogenase deficiency is a common genetic condition, with a global prevalence of approximately 4.9%, affecting over 400 million individuals worldwide. It is important to recognize that glucose-6-phosphate dehydrogenase deficiency can still be life-threatening if not promptly diagnosed and managed. Effective management often includes interventions as blood transfusions, but with appropriate care, full recovery from favism without lasting complications is the expected outcome.
== History and clinical trials == In the 1970s, Jens Juul Holst and Joel Habener began research on GLP-1, initially in relation to duodenal ulcer disease. They were examining hormones secreted during eating, and testing them on pig pancreases, leading to the discovery of GLP-1's significant effects in 1988. Their work, which later contributed significantly to diabetes and obesity treatments, earned them and Daniel J. Drucker the 2020 Warren Alpert Foundation Prize. Research continued, and in 1993, Michael Nauck managed to infuse GLP-1 into people with type 2 diabetes, stimulating insulin while inhibiting glucagon and bringing blood glucose to normal levels. However, treating diabetes with GLP-1 hormones resulted in significant side effects, leading researchers financed by Novo Nordisk to start looking to develop a suitable compound for therapeutic use. In 1998, a team of researchers at Novo Nordisk led by Lotte Bjerre Knudsen developed liraglutide, a GLP-1 receptor agonist that could be used to treat diabetes. This was followed by the development of semaglutide by a team of researchers at Novo Nordisk, including Jesper Lau, Thomas Kruse, and Paw Bloch.
Sources: en.wikipedia.org
It is a complex of a three-amino-acid peptide, glycine, histidine and lysine, bound to a single copper(II) ion. The metal is held mainly by the histidine side chain and the peptide backbone. Most commercial material is supplied as an acetate salt rather than as the free complex.
The free peptide was reported in 1973 by Loren Pickart, who isolated it from human plasma. Its copper-binding behaviour was characterised over the following years. The metal-bound form has been the subject of most later research.
Yes. Copper tripeptide-1 is the name used in cosmetic ingredient labelling, while GHK-Cu is the shorthand found in the scientific literature. Both refer to the same peptide-copper complex, and the two terms are interchangeable in most technical documents.
GHK denotes the unbound chain of three amino acids. GHK-Cu describes the form in which a copper(II) ion is held by that chain. The two are not interchangeable in solution, since charge, molecular weight, and reactivity differ.